yanping deng

Dr. yanping deng

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2008 in Electrochemistry Communications
Verified
Journal Article
Closed access
YDyanping deng
yanping deng
WHWei Huang
Wei Huang
Xin ChenXin Chen
Xin Chen
ZLZelin Li
Zelin Li

1 November 2020 in Polymer Degradation and Stability
Verified
Journal Article
Closed access
SHSheng Huang
Sheng Huang
HCHua-Jiao Chen
Hua-Jiao Chen
YDyanping deng
yanping deng
XYXiu-Hua You
Xiu-Hua You
QFQuan-Hui Fang
Quan-Hui Fang
MLMei Lin
Mei Lin

23 October 2014 in Molecular BioSystems
Verified
Journal Article
Closed access
PDF file
Bingpeng YANBingpeng YAN
Bingpeng YAN
YDyanping deng
yanping deng
JHJinjun Hou
Jinjun Hou
QBQirui Bi
Qirui Bi
MYMin Yang
Min Yang
De-an  GuoDe-an Guo
De-an Guo
Undoubtedly, metabonomics can reveal the comprehensive efficacies of traditional Chinese medicine (TCM) formulae and its complex mechanism at the molecular biological level. In this study, an attempt was made to address the pretreatment effect of a TCM formula. In this case, as a critical point, we should first know how to really reflect the various endogenous metabolites in a disease status before a TCM formula is employed in a therapeutic procedure. Here, we explored an approach that combined high resolution LTQ-Orbitrap mass spectrometry with a spike-in method to characterize endogenous metabolites in acute myocardial ischemia (AMI) rats. As a result, 19 potential biomarkers in rat plasma were identified and 10 related disturbed pathways were perturbed in the early stages of AMI development. Subsequently, the metabonomics method was applied to investigate the pretreatment effect of the TCM formula named the Danqi Tongmai tablet (DQTM). The results revealed that the DQTM pretreatment could reduce the AMI injury and partially regulate the perturbed TCA cycle and amino and nucleotide metabolism, which were presumable related to energy metabolism and myocardial cells apoptosis/necrosis. In conclusion, UHPLC-LTQ-Orbitrap MS combined with a spike-in method were successfully applied to the metabonomics analysis of DQTM, which demonstrated that not only a comprehensive metabolic profile in the early stages of AMI development was achieved, but also that the underlying holistic efficacies were assessed and it was helpful to understand the possible mechanism of pretreatment with DQTM.

1 February 2015 in Journal of the Chinese Medical Association
Verified
Journal Article
Closed access
YDyanping deng
yanping deng
TZTingting Zhang
Tingting Zhang
FTFukang Teng
Fukang Teng
DLDefang Li
Defang Li
AXAnd Feng Xu
And Feng Xu
BJBaohong Jiang
Baohong Jiang
The herb pair of Salvia miltiorrhiza and Panax notoginseng has widely been used for improving coronary and cerebral circulation in China. However, the exact contribution of the major active components of S. miltiorrhiza and P. notoginseng to cardioprotection is far from clear. In the present study, three representative ingredients, salvianolic acid B (SalB) from S. miltiorrhiza and ginsenoside Rg1 (Rg1) and ginsenoside Rb1 (Rb1) from P. notoginseng, were selected to elucidate the mechanism of the herb pair at the ingredient level. The purity of SalB, Rg1, and Rb1 was >99%, as detected by high-performance liquid chromatography. Acute myocardial infarction was introduced by ligation of the left anterior descending coronary artery near the main pulmonary artery. Cardiac contractility was detected through a Mikro-tipped catheter, and cardiac infarct size was determined using triphenyltetrazolium chloride stain. The combination of SalB and Rg1, and not the combination of SalB and Rb1, improved heart contractility in rats with myocardial infarction. The different contributions of Rg1 and Rb1, in combination with SalB, to cardioprotection provides further direction to optimize and modernize the herbal medicines containing S. miltiorrhiza and P. notoginseng. The combination of SalB and Rg1 may provide potential protection against myocardial infarction.

19 May 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
XGXin Guo
Xin Guo
MWMin Wu
Min Wu
YDyanping deng
yanping deng
YLYan Liu
Yan Liu
YLYanpeng Liu
Yanpeng Liu
JXJianhua Xu
Jianhua Xu
The poor bioavailability of curcumin and its derivatives limits their antitumor efficacy and clinical translation. Although curcumin derivative C210 has more potent antitumor activity than curcumin, it has a similar deficiency to curcumin. In order to improve its bioavailability and accordingly enhance its antitumor activity in vivo, we developed a redox-responsive lipidic prodrug nano-delivery system of C210. Briefly, we synthesized three conjugates of C210 and oleyl alcohol (OA) via different linkages containing single sulfur/disulfide/carbon bonds and prepared their nanoparticles using a nanoprecipitation method. The prodrugs required only a very small amount of DSPE-PEG2000 as a stabilizer to self-assemble in aqueous solution to form nanoparticles (NPs) with a high drug loading capacity (~50%). Among them, the prodrug (single sulfur bond) nanoparticles (C210-S-OA NPs) were the most sensitive to the intracellular redox level of cancer cells; therefore, they could rapidly release C210 in cancer cells and thus had the strongest cytotoxicity to cancer cells. Furthermore, C210-S-OA NPs exerted a dramatic improvement in its pharmacokinetic behavior; that is, the area under the curve (AUC), mean retention time and accumulation in tumor tissue were 10, 7 and 3 folds that of free C210, respectively. Thus, C210-S-OA NPs exhibited the strongest antitumor activity in vivo than C210 or other prodrug NPs in mouse models of breast cancer and liver cancer. The results demonstrated that the novel prodrug self-assembled redox-responsive nano-delivery platform was able to improve the bioavailability and antitumor activity of curcumin derivative C210, which provides a basis for further clinical applications of curcumin and its derivatives.

1 November 2019 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
YDyanping deng
yanping deng
GZGuifeng Zhong
Guifeng Zhong
YWYi Wang
Yi Wang
NWNi Wang
Ni Wang
QYQing Yu
Qing Yu
XYXiangbin Yu
Xiangbin Yu